Viking Therapeutics (VKTX) Other Accumulated Expenses (2014 - 2026)

Viking Therapeutics has reported Other Accumulated Expenses for 13 years, with the latest figure at $40.5 million in Q2 2026.

• Quarterly Other Accumulated Expenses rose 55.6% year-over-year to $40.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $40.5 million (up 55.6% YoY) and the FY2025 annual result came in at $23.3 million, up 36.05% from the prior year.
• Other Accumulated Expenses improved to $40.5 million in Q2 2026 per VKTX's latest filing, from $39.1 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $40.5 million in Q2 2026 and troughed at $7.4 million in Q3 2023.
• A 5-year average of $17.9 million and a median of $13.4 million in 2022 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2025 and 2026: Other Accumulated Expenses slumped 58.22% in 2025, then soared 244.17% in 2026.
• Over 5 years, Other Accumulated Expenses stood at $13.1 million in 2022, then declined by 13.84% to $11.3 million in 2023, then soared by 51.44% to $17.1 million in 2024, then soared by 36.05% to $23.3 million in 2025, then surged by 73.9% to $40.5 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $40.5 million, $39.1 million, and $23.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.